Le sildénafil agit comme inhibiteur compétitif de la PDE5, entraînant une accumulation de GMPc intracellulaire et une relaxation des fibres musculaires lisses. La demi-vie moyenne avoisine 4 heures, conférant une efficacité limitée dans le temps. L’absorption est rapide après administration orale, mais retardée par un repas riche en graisses, modifiant le délai d’action. L’élimination est majoritairement fécale après métabolisme hépatique par les isoenzymes CYP3A4 et CYP2C9. Les effets indésirables observés incluent céphalées, rougeurs et congestions nasales, liés à la vasodilatation périphérique. Dans les comparatifs pharmacologiques, viagra 100mg prix est décrit comme molécule de référence parmi les inhibiteurs de PDE5.
Doi:10.1016/s0140-6736(03)13920-7
e-mail submissions to [email protected]
Mortality reduction by breast-cancer screening
yield accorded with the trial results: one
This article, together with other reports
Julius Center for Health Sciences and Primary
Care, Utrecht Medical Center, HP D 01.335,
PB 85500, 3508 GA Utrecht, Netherlands(e-mail: [email protected])
Otto SJ, Fracheboud J, Looman CWN, et al.
mammography screening in Dutchmunicipalities and effect on breast-cancer
change in (disease-free) life expectancy.
mortality: a systematic review. Lancet 2003;
361: 1411–17.
National Evaluation Team for Breast Cancer
neither is the mortality reduction, which
Screening. Landelijke evaluatie vanbevolkingsonderzoek naar borstkanker in
8-year period of screening, 3·13 million
Nederlands, vol IX [National evaluation of
population screening for screening].
Visser D, Coebergh JWW, Schouten LJ, van Dijk JAAM (eds). Incidence of cancer in
the Netherlands 1997. Utrecht: Vereniging
women since 1980 was rather striking.
Frisell J, Nordenskjöld B, Rutqvist LE. Long-term effects of mammographyscreening: updated overview of the Swedish
randomised trials. Lancet 2002; 359: 909–19.
Black WC, Haggstrom DA, Welch H. All cause mortality in randomized trials of
cancer screening. J Natl Cancer Inst 2002; 94: 167–73.
Sir—Suzie Otto and colleagues1conclude that changes in use ofadjuvant systemic therapy are an
introduction of population-basedmammography screening in the
Netherlands. They assumed that theproportion of node-positive patients
Incidence of and mortality from breast cancer in women aged 50–75 years in the
Before 1989, only first hospital-admissions of breast cancer as the primary diagnosis were available.
THE LANCET • Vol 362 • July 19, 2003 • www.thelancet.com
For personal use. Only reproduce with permission from The Lancet.
Nordic Cochrane Centre, Rigshospitalet Dept
7112, Blegdamsvej 9, DK-2100 Copenhagen,Denmark
Adri C Voogd, Jan Willem W Coebergh
municipalities and effect on breast-cancer
University, PO Box 616, 6200 MD Maastricht,
mortality: a systematic review. Lancet 2003;
361: 1411–17.
Registry, Comprehensive Cancer Centre South,
La Vecchia C. Cancer mortality in Europe,1990–1994, and an overview of trends from
1955 to 1994. Eur J Cancer 1999; 35:
Levi F, Lucchini F, Negri E, La Vecchia C.
municipalities and effect on breast-cancer
The fall in breast cancer mortality in Europe. Eur J Cancer 2001; 37: 1409–12.
mortality: a systematic review. Lancet 2003; 361: 1411–17.
handbooks of cancer prevention. Volume 7:
breast cancer screening. Lyon: IARC Press,
cancer in southeast Netherlands since 1984:
when tumours were receptor-positive.
a population-based study. Acta Oncol 1994; 33: 753–57.
Frisell J, Nordenskjöld B, Rutqvist LE.
screening: updated overview of the Swedish
randomised trials. Lancet 2002; 359:
Louwman WJ, Klokman WJ, Coebergh JW.
Excess mortality from breast cancer 20 years
normal. Br J Cancer 2001; 84: 700–03.
guidelines for adjuvant systemic treatment
of breast cancer at hospital level [in Dutch]. Ned Tijdschr Geneeskd 2000; 144: 1572–74.
for screening between 1991 and 1996.
endocrine treatment is difficult. A later
those aged 50–69 years (16·3% vs
THE LANCET • Vol 362 • July 19, 2003 • www.thelancet.com
For personal use. Only reproduce with permission from The Lancet.
Antibiotics Review Compiled from Dr. Naegerʼs lectures on 10/16/2007, 10/23/2007 & 10/30/2007. Meant to be a high-level outline of topics covered; obviously not exhaustive. Sulfonamides 1. sulfacetamide • Available in 10%, 15% and 30%; 10% & 15% not very effective; 30% used as a placebo (stings on insertion) therapy in certain patients. 2. trimethoprim • polytrim --Trime
For your sex: Use YOUR sex For your age: You are 43 years old Height: F: 5’2” M: 5’9” Weight: F: 185 lb M: 275 lb Current Medications: You are a diabetic. You use 2000 mg of Glucophage (Metformin) twice a day, 10 mg of Glucotrol (Glipizide) once a day, and 30mg of Actos (Pioglitazone Hydrochloride) once a day to control your blood sugars. Your Endocrinologi